MaxCyte Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $3.7
- Today's High:
- $3.83
- Open Price:
- $3.8
- 52W Low:
- $3.45
- 52W High:
- $7.5
- Prev. Close:
- $3.82
- Volume:
- 643676
Company Statistics
- Market Cap.:
- $382.97 million
- Book Value:
- 2.337
- Revenue TTM:
- $40.69 million
- Operating Margin TTM:
- -100.07%
- Gross Profit TTM:
- $39.16 million
- Profit Margin:
- -80.22%
- Return on Assets TTM:
- -9.07%
- Return on Equity TTM:
- -13.1%
Company Profile
MaxCyte Inc had its IPO on 2021-07-30 under the ticker symbol MXCT.
The company operates in the Healthcare sector and Medical Devices industry. MaxCyte Inc has a staff strength of 125 employees.
Stock update
Shares of MaxCyte Inc opened at $3.8 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $3.7 - $3.83, and closed at $3.76.
This is a -1.57% slip from the previous day's closing price.
A total volume of 643,676 shares were traded at the close of the day’s session.
In the last one week, shares of MaxCyte Inc have increased by +1.62%.
MaxCyte Inc's Key Ratios
MaxCyte Inc has a market cap of $382.97 million, indicating a price to book ratio of 2.1618 and a price to sales ratio of 13.1478.
In the last 12-months MaxCyte Inc’s revenue was $40.69 million with a gross profit of $39.16 million and an EBITDA of $-37062300. The EBITDA ratio measures MaxCyte Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, MaxCyte Inc’s operating margin was -100.07% while its return on assets stood at -9.07% with a return of equity of -13.1%.
In Q2, MaxCyte Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 5.9%.
MaxCyte Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.32 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into MaxCyte Inc’s profitability.
MaxCyte Inc stock is trading at a EV to sales ratio of 8.1908 and a EV to EBITDA ratio of -16.1281. Its price to sales ratio in the trailing 12-months stood at 13.1478.
MaxCyte Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $271.20 million
- Total Liabilities
- $13.20 million
- Operating Cash Flow
- $26.67 million
- Capital Expenditure
- $507000
- Dividend Payout Ratio
- 0%
MaxCyte Inc ended 2024 with $271.20 million in total assets and $0 in total liabilities. Its intangible assets were valued at $271.20 million while shareholder equity stood at $240.98 million.
MaxCyte Inc ended 2024 with $0 in deferred long-term liabilities, $13.20 million in other current liabilities, 1031400.00 in common stock, $-159268700.00 in retained earnings and $0 in goodwill. Its cash balance stood at $54.56 million and cash and short-term investments were $216.11 million. The company’s total short-term debt was $498,600 while long-term debt stood at $0.
MaxCyte Inc’s total current assets stands at $236.62 million while long-term investments were $0 and short-term investments were $161.55 million. Its net receivables were $7.61 million compared to accounts payable of $1.60 million and inventory worth $11.02 million.
In 2024, MaxCyte Inc's operating cash flow was $26.67 million while its capital expenditure stood at $507000.
Comparatively, MaxCyte Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $3.76
- 52-Week High
- $7.5
- 52-Week Low
- $3.45
- Analyst Target Price
- $10.33
MaxCyte Inc stock is currently trading at $3.76 per share. It touched a 52-week high of $7.5 and a 52-week low of $7.5. Analysts tracking the stock have a 12-month average target price of $10.33.
Its 50-day moving average was $4.22 and 200-day moving average was $4.72 The short ratio stood at 5.88 indicating a short percent outstanding of 0%.
Around 119% of the company’s stock are held by insiders while 7621.4% are held by institutions.
Frequently Asked Questions About MaxCyte Inc
Similar Industry Stocks (Medical Devices)
Most Active
Top Gainers
Top Losers
About
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.